Autopsy report · NCT05582707

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

“Loss of Financial Sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months before it started.
• Ran for about 2 years 8 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Intracerebral Haemorrhage, Intraventricular

Interventions

Pioglitazone 15mg

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
  “loss of sponsor support” (91% match in meaning)
• Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use
  “Lost funding from sponsor” (87% match in meaning)
• A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
  “Sponsor lost funding” (86% match in meaning)
• Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
  “Sponsor terminated financial support” (86% match in meaning)
• Mepolizumab for Eosinophilic Fasciitis
  “Funding lost from Sponsor.” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.